BioStar Capital is a value-add investment firm focused on transformational medical device technologies in cardiovascular and orthopaedic medicine. Combining the insight of experienced investment professionals and world-renowned medical thought leaders, BioStar Capital identifies proprietary technologies that serve unmet patient needs and fit the acquisition criteria of leading medical device companies. BioStar Capital fills an important gap in medical device innovation and provides operational skills and clinical expertise in addition to capital, enabling the firm to actively mitigate risk, optimize product development, and secure successful exit. The firm has invested in over 30 med-tech companies, many of which have been acquired by a major medical device manufacturer.
BioStar News
Portfolio News
October 10, 2016
Professor Ian Meredith, Cardiovascular Medical Venture Partner for BioStar, To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
October 25, 2019
Corindus Vascular Robotics, Inc. Stockholders Approve Acquisition by Siemens Healthineers
September 17, 2019
Foldax®, Inc. Successfully Completes First-In-Human Use of Next-Generation Tria Polymer Heart Valve for the Treatment of Aortic Valve Disease
Active Portfolio Companies
